AviadoBio has extended its exclusive licence agreement with King’s College London to apply the vMiX ribonucleic acid interference (RNAi) gene-silencing platform across all human therapeutic areas. The ...
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results